Navigation Links
Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China

DURHAM, N.C., Oct. 1, 2013 /PRNewswire/ -- Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science), for the clinical development, marketing and distribution of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) in the People's Republic of China ("PRC"), including Hong Kong and Macau. Hefei Life Science, based in Anhui Province in Eastern China, will fund and manage clinical development programs necessary to obtain regulatory approval for MiStent SES in the Chinese markets. 

Under the agreement, Micell will manufacture and supply MiStent SES for clinical and commercial use. Sinopharm, based in Shanghai and the first Chinese pharmaceutical company included in the Fortune Global 500 list, will provide distribution and logistical support while SinoMedCare, of Shanghai, will contribute marketing and sales support. The agreement includes annual purchase commitments commencing upon regulatory approval of MiStent SES for commercial sale in China.

"This agreement creates a strong opportunity for MiStent SES to enter the Chinese market and build upon our recent CE Mark approval in Europe," commented Arthur J. Benvenuto, Micell's Chairman and Chief Executive Officer. "Sinopharm and SinoMedCare bring strengths to this partnership with Hefei Life Science that we expect will make this important medical innovation in the coronary stent market readily accessible to patients in Greater China."

About the MiStent SES

The MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) is designed to optimize healing in patients with coronary artery disease. MiStent's rapidly absorbable coating is intended to precisely and consistently control drug elution and limit polymer exposure duration to reduce the safety risks associated with current commercially available drug-eluting stent technologies.

The innovative MiStent SES system includes a proprietary stent coating that contains crystalline drug (sirolimus) and an absorbable polymer. The coating provides controlled and sustained release of therapeutic levels of drug as the polymer softens and disperses from the stent into the adjacent tissue. These properties are intended to enhance safety as compared to conventional permanent polymer DES.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent SES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility.

Results of animal studies have determined that the coating is cleared from the stent in 45 to 60 days leaving a bare metal stent and the polymer is completely absorbed into the surrounding tissue within 90 days to promote long-term patency and compatibility with the artery.

Micell was granted CE (Conformite Europeenne) Mark approval for MiStent SES for the European Economic Union in June 2013, but is not approved in the United States or any other countries.  A two year follow-up of DESSOLVE I and II clinical studies subjects was completed in 2013, and they currently are undergoing long-term follow-up.

About Micell Technologies Inc.

Micell Technologies is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-coated balloon for vascular interventions. Visit us at  Cooley LLP represented Micell in the transaction.

About Hefei Life Science

Hefei Life Science was established in Hefei Economic and Technological Development Area, Anhui P.R. China in December 2005.  The main objective of the company is to bring high-tech bio-pharmaceutical projects with internationally advanced level and good market prospects to Hefei Life Science Park.

Hefei Life Science is engaged in the development and production of biological products, and distribution of pharmaceutical products and medical devices. The Company's mission is to provide our patients with pharmaceutical products and medical devices with high quality, high efficacy, and safety profile for the benefit of patients.

Hefei Tianmai Biotechnology Development Co.Ltd. ("HTBT"), a subsidiary of Hefei Life Science, has established an advanced manufacturing plant in accordance with European standards and has successfully developed recombinant human insulin. HTBT is in the process of developing insulin analogues and plans to sell the products around the world.

About Sinopharm

Sinopharm Group Co., Ltd and its subsidiaries ("Sinopharm Group") have integrated operations in the following business segments, namely pharmaceutical distribution segment, retail pharmacy segment and other business segment.

The Sinopharm Group is the industry leader in the distribution of pharmaceutical and healthcare products in China both in terms of its market share and the geographical coverage of its distribution network. As a leading pharmaceutical distributor in China, the Sinopharm Group will benefit from the rapid growth, consolidation, and structural reform in the pharmaceutical and healthcare industry in the PRC.

The Sinopharm Group has rapidly increased its market share and profits in a highly fragmented industry by taking advantage of its economies of scale and nationwide distribution network, through which the Sinopharm Group offers a wide range of value-added supply chain services for its customers and suppliers.

About SinoMedCare

SinoMedCare is a leading, innovation-driven pharmaceutical marketing platform in the PRC. SinoMedCare grasps the development directions of the China pharma industry, and provides solutions to the challenges faced by foreign manufacturers in market access and market penetration.

SinoMedCare is the first marketing platform in the pharma industry in China which focuses on supporting multinationals penetrating the broader market, upgrading and modernizing distribution channel in tier 3 cities, and providing a complete package of value-added services. SinoMedCare has invested heavily in building up the first refined operations service platform in the industry based on cloud technology, and elevated marketing services in the large market to a new level.

The investors of SinoMedCare include professional venture capital firm VIVO.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements that can be identified by the fact that they do not relate strictly to historical or current facts. Forward looking statements include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance in connection with the results of a post-marketing clinical program and the commercialization and sale of the MiStent SES® in Europe and other markets. We caution readers that the forward looking statements contained in this press release are predictions based on our current analysis of and expectations about future events and speak only as of the date of this press release.  These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to the following:  the results of any further clinical trials and studies; our ability to obtain regulatory approval of the MiStent SES in other jurisdictions; the successful development and commercialization of the MiStent SES in Europe and other markets; the ability of the MiStent SES to effectively and successfully compete with current commercially available drug-eluting stent technologies in Europe and other markets; and our ability to maintain and protect our proprietary stent coating technology. Actual results, performance or achievements could differ materially and adversely from those expressed or implied by any forward looking statement contained in this press release.

Micell, Micell Technologies, the Micell Logo, MiStent and MiStent SES are among the trademarks of Micell Technologies, Inc.

Contact: Micell Technologies
Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104

SOURCE Micell Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
2. Micell Technologies Receives CE Mark Approval for MiStent SES
3. Micell Technologies Announces Issuance of Core Technology Patent
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. LaserLock Technologies Applauds the U.S. House Passage of the Drug Quality and Security Act
6. Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement
7. RF Technologies Introduces New CodeWatch Designs for Wandering Management Solution
8. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
9. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
10. BioLife Solutions and SAVSU Technologies Announce Exclusive Distribution Agreement
11. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
Post Your Comments:
(Date:10/8/2015)... Oct. 9, 2015 Johnson & Johnson (NYSE: ... immunogenicity clinical trial in Sierra Leone ... Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first ... first study conducted of Janssen,s Ebola prime-boost vaccine regimen in ... Sierra Leone,s Kambia district, where ...
(Date:10/8/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a ... diseases, today announced that clinical data for the ... at the 2015 American College of Gastroenterology (ACG) ... sustained response in IBS-C patients enrolled in the ... trial. The meeting will be held in ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... cell-free molecular diagnostics, today announced the presentation of ... use of its Precision Cancer Monitoring SM ... can be critical for physicians to determine appropriate ... chief scientific officer of Trovagene is delivering the ...
Breaking Medicine Technology:
... February is American Heart Month and a time when ... on their family history of heart disease and recommit ... teaming up with the makers of Bayer® Aspirin and ... to raise $100,000 for the fight against heart disease. ...
... 2012 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Leerink Swann 2012 Global Healthcare Conference to be ... New York City.  Mr. Adrian Adams, Chief Executive Officer ... the Company and its product pipeline at 10:30 a.m. ...
Cached Medicine Technology:
(Date:10/9/2015)... ... , ... With the FCPX LUT Vibrance pack from Pixel Film Studios, editors ... Lookup Table that contains a mathematical formula for modifying an image. The LUT changes ... with 60 vibrant CUBE LUT files. , Inspired by many YouTube make-up ...
(Date:10/9/2015)... ... 09, 2015 , ... Dentist in Huntington Beach , ... that uses clear, plastic aligners. This alternative to braces has become wildly popular ... patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so patients ...
(Date:10/9/2015)... Stockton, CA (PRWEB) , ... October 09, 2015 ... ... year anniversary of their “Agents of Change” program, a community improvement initiative that ... The newest charity to benefit from the assistance of Confidence Plus Insurance is ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... ... , ... Most people assume that Chinese food is more nutritious than American ... T’ai Chi Master and integrative medicine guru Steven Aung, MD agrees with that assessment, ... that they potentially complement one another, with each supplying nutritional elements the other may ...
Breaking Medicine News(10 mins):
... Sales and Marketing Veteran to Drive International Retail Expansion, ... Group and New WrinkleFree Brand Line ExtensionIRVINE, Calif., Jan. ... developer and distributor of medically developed and efficacy-based skin ... mass market retail locations throughout the U.S., announced today ...
... The following statement can be attributed to Michael ... has consistently said two things: We are not ... But we have urged public policy makers to ... merger without conditions, because without conditions the merger ...
... (Nasdaq: OMCL ), a leading provider of system solutions to acute healthcare ... quarter 2008 financial results. , What: Omnicell ... webcast, When: January ... Lipps, chairman, president and chief executive officer, ...
... Maine, Jan. 21 IDEXX Laboratories, Inc. (Nasdaq: ... quarter and full-year financial results for Friday, January 30, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... can lead to failure, , , WEDNESDAY, Jan. 21 (HealthDay ... a common cause of kidney transplant failure may help ... polyomavirus nephropathy, which affects about 9 percent of kidney ... adults but can cause serious problems for people with ...
... CAMBRIDGE, Mass. -- Schizophrenia may blur the boundary between ... that is involved in self-reflection, and thus causing an ... brain imaging study has found. , The traditional ... and emotions that characterize the disease are caused by ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: